Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
Iovance Biotherapeutics heads into its November 6 earnings print with the short book still contracting, analyst targets moving sharply higher, and options traders finally starting to hedge.
The short unwind has now taken on genuine momentum. Short interest dropped 19% on the week to 15.4% of the free float, or roughly 61 million shares. That is the largest weekly decline since the covering began. From the early September peak of around 102 million shares, bears have now shed 40 million positions, a reduction of nearly 40% in six weeks. The remaining 61 million shares are still on average underwater, built when the stock traded below $9. At $13.62, that position carries significant embedded losses. The lending market offers no mechanical pressure. Availability has loosened further to 414%, meaning more than four shares remain available to borrow for every one lent out. Cost to borrow, at 0.48%, has ticked up 30% on the week but remains trivial in absolute terms. The covering pace is being driven by earnings fear and P&L pain, not any squeeze dynamic.
The Street has been unusually active, and the direction is consistently bullish. Barclays raised its target to $18 from $15 this week, maintaining Overweight. That follows Wells Fargo lifting to $18 from $14 at the end of September and Goldman Sachs reinstating with a Buy and a $15 target. HC Wainwright went furthest, moving to $20 from $9. The lone sceptic in the recent flow is Baird, which raised its Neutral target to $11 from $6, acknowledging the commercial traction while staying on the sidelines. The mean target now sits at $14.40, close to the current price, but several of the most recent moves are well above that average. The analyst recommendation factor ranks in the 91st percentile of the ORTEX universe, the highest-scoring dimension in the factor profile. Bulls point to AMTAGVI and Proleukin delivering $99.3 million in Q2 revenue, up 66% year on year, with full-year guidance raised to $410 million to $420 million. Bears flag the dependence on continued clinical success, emerging CAR-T competition, and the memory of weak AMTAGVI uptake earlier in the year.
Options positioning has shifted more defensive this week. The put/call ratio has climbed to 0.57, the highest reading of the past year and about 1.4 standard deviations above its 20-day average of 0.51. That is a modest but clear pivot: after weeks of predominantly call-heavy flow during the stock's run from below $9, traders are now buying more downside protection. The timing aligns with the stock retreating 7% on the week even as the broader covering story continued.
Institutional ownership has also moved in interesting ways. BlackRock added nearly 5.9 million shares in the quarter to September 30, bringing its stake to 8.2% of shares outstanding. State Street added 7 million shares in the same period, crossing the 5% threshold and filing a fresh Schedule 13G. No activist 13D holder is on the register. Perceptive Advisors, which previously held 7.3%, has reduced to 3.8% as of its last filing in May 2025. The 13G/A register reflects passive accumulation by index managers rather than activist pressure, consistent with the CRSP US Small index rebalance: ORTEX puts a 70% probability on a share-count increase at the December 2026 quarterly review, implying around $93 million of forced buying by index trackers on December 22.
The last earnings print, in August, produced a one-day move of 46% and a five-day move of 50%. The November 6 result lands with short interest still at 15% of the float, analyst targets clustered well above the current price, and a stock that has risen nearly 400% year to date. What to watch is whether the remaining short base accelerates its exit in the 20 days before the print, or holds and waits for the data.
See the live data behind this article on ORTEX.
Open IOVA on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
